Coherus Biosciences Stock Performance
| CHRS Stock | USD 1.03 0.02 1.90% |
The firm shows a Beta (market volatility) of 0.99, which signifies possible diversification benefits within a given portfolio. Coherus BioSciences returns are very sensitive to returns on the market. As the market goes up or down, Coherus BioSciences is expected to follow. At this point, Coherus BioSciences has a negative expected return of -0.48%. Please make sure to confirm Coherus BioSciences' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Coherus BioSciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Coherus BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Jacobs Levy Equity Management Inc. Has 262,000 Stock Holdings in Coherus BioSciences, Inc. - MarketBeat | 12/11/2024 |
2 | Disposition of 2073 shares by Paul Reider of Coherus BioSciences at 1.61 subject to Rule 16b-3 | 12/13/2024 |
3 | Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | 12/18/2024 |
4 | Acquisition by Paul Reider of 160000 shares of Coherus BioSciences at 1.66 subject to Rule 16b-3 | 01/03/2025 |
5 | Disposition of 1711 shares by Bryan Mcmichael of Coherus BioSciences at 1.57 subject to Rule 16b-3 | 01/07/2025 |
6 | Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/08/2025 |
7 | Acquisition by Dennis Lanfear of 575000 shares of Coherus BioSciences at 1.47 subject to Rule 16b-3 | 01/10/2025 |
8 | Disposition of 5437 shares by Vladimir Vexler of Coherus BioSciences at 9.87 subject to Rule 16b-3 | 01/17/2025 |
9 | Coherus BioSciencess SWOT analysis stock faces headwinds amid oncology pivot - Investing.com | 01/23/2025 |
10 | BlackRock, Inc. Reduces Stake in Coherus BioSciences Inc | 02/05/2025 |
11 | Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference | 02/24/2025 |
12 | Acquisition by Paul Reider of 160000 shares of Coherus BioSciences at 3.14 subject to Rule 16b-3 | 02/28/2025 |
13 | Institutional owners may consider drastic measures as Coherus BioSciences, Inc.s recent US17m drop adds to long-term losses | 03/04/2025 |
| Begin Period Cash Flow | 64 M |
Coherus |
Coherus BioSciences Relative Risk vs. Return Landscape
If you would invest 151.00 in Coherus BioSciences on December 5, 2024 and sell it today you would lose (48.00) from holding Coherus BioSciences or give up 31.79% of portfolio value over 90 days. Coherus BioSciences is currently does not generate positive expected returns and assumes 5.6051% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Coherus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Coherus BioSciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coherus BioSciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Coherus BioSciences, and traders can use it to determine the average amount a Coherus BioSciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0863
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CHRS |
Estimated Market Risk
| 5.61 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Coherus BioSciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Coherus BioSciences by adding Coherus BioSciences to a well-diversified portfolio.
Coherus BioSciences Fundamentals Growth
Coherus Stock prices reflect investors' perceptions of the future prospects and financial health of Coherus BioSciences, and Coherus BioSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Coherus Stock performance.
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 293.87 M | ||||
| Shares Outstanding | 115.89 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.40 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | 136.08 M | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Earnings Per Share | (0.09) X | ||||
| Market Capitalization | 121.68 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
About Coherus BioSciences Performance
Assessing Coherus BioSciences' fundamental ratios provides investors with valuable insights into Coherus BioSciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Coherus BioSciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 126.34 | 120.02 | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.41 | 1.97 |
Things to note about Coherus BioSciences performance evaluation
Checking the ongoing alerts about Coherus BioSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Coherus BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Coherus BioSciences generated a negative expected return over the last 90 days | |
| Coherus BioSciences has high historical volatility and very poor performance | |
| Coherus BioSciences has some characteristics of a very speculative penny stock | |
| Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 257.24 M. Net Loss for the year was (237.89 M) with profit before overhead, payroll, taxes, and interest of 136.08 M. | |
| Coherus BioSciences currently holds about 275.48 M in cash with (174.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Coherus BioSciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Institutional owners may consider drastic measures as Coherus BioSciences, Inc.s recent US17m drop adds to long-term losses |
- Analyzing Coherus BioSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Coherus BioSciences' stock is overvalued or undervalued compared to its peers.
- Examining Coherus BioSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Coherus BioSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Coherus BioSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Coherus BioSciences' stock. These opinions can provide insight into Coherus BioSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.